

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

September 1, 2009

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED)**

*Commission File No. 001-33057*

---

**CATALYST PHARMACEUTICAL PARTNERS, INC.**

(Exact Name Of Registrant As Specified In Its Charter)

---

**Delaware**  
(State Or Other Jurisdiction Of  
Incorporation Or Organization)

**76-0837053**  
(IRS Employer  
Identification No.)

**355 Alhambra Circle, Suite 1370  
Coral Gables, Florida 33134**  
(Address Of Principal Executive Offices)

**(305) 529-2522**  
(Registrant's Telephone Number, Including Area Code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing**

On September 1, 2009, Catalyst Pharmaceutical Partners, Inc. (the "Company") was notified by the Nasdaq Stock Market that its application to transfer the listing of the Company's common stock from the Nasdaq Global Market to the Nasdaq Capital Market was approved. The Company's common stock will continue to trade under the ticker symbol "CPRX" and began trading on the Nasdaq Capital Market on September 3, 2009.

On September 2, 2009, the Company issued a press release announcing the transfer. A copy of the Company's press release is Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press release issued by the Company on September 2, 2009.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceutical Partners, Inc.**

By: /s/ Jack Weinstein  
Jack Weinstein  
Vice President, Treasurer and CFO

Dated: September 3, 2009

---

## Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release issued by the Company on September 2, 2009.

**NEWS RELEASE****FOR IMMEDIATE RELEASE***For Further Information Contact:*

Jack Weinstein, Catalyst Pharmaceutical  
Chief Financial Officer  
(201) 934-4201  
[jweinstein@catalystpharma.com](mailto:jweinstein@catalystpharma.com)

Melody Carey, Rx Communications Group  
Co-President  
(917) 322-2571  
[mcarey@rxir.com](mailto:mcarey@rxir.com)

**CATALYST PHARMACEUTICAL PARTNERS TO TRANSFER TO NASDAQ CAPITAL MARKET**

**CORAL GABLES, FL, September 2, 2009** — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) has received approval from The NASDAQ Stock Market to transfer the listing of its common stock from The NASDAQ Global Market® to The NASDAQ Capital Market®. The transfer will be effective at the opening of the market on September 3, 2009. Catalyst will continue to trade under the symbol “CPRX” with no impact on the ability of investors to trade the stock.

The NASDAQ Capital Market® is a continuous trading market that operates in the same manner as The NASDAQ Global Market®. The NASDAQ Capital Market® includes the securities of approximately 450 companies. All companies listed on The NASDAQ Capital Market® must meet certain financial requirements and adhere to NASDAQ’s corporate governance standards.

**About Catalyst Pharmaceutical Partners**

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. For more information about the Company, go to [www.catalystpharma.com](http://www.catalystpharma.com).

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results in future periods to differ materially from forecasted results. A number of factors, including those disclosed in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect the Company. Copies of the Company’s filings with the SEC are available from the SEC, may be found on the Company’s website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.